|
|
| |
PAY FOR CHARGES |
PRE-SUBMISSION ENQUIRY SERVICE MANUSCRIPT FORMAT
 GUIDELINES FOR CONTRIBUTORS Upon receipt of an author's submission, the manuscript deemed suitable for the journal will be assigned to a member of the Editorial Board who has agreed to undertake its rapid review, soliciting the opinions of independent referees. After review, the editors will move to accept, reject, or invite a revised submission depending on the novelty, scholarship, and general appeal of the work to a broad audience. Following acceptance of a manuscript, papers will be posted on the Web (free online access) with PubMed citation prior to the print copy. Offprints must be ordered when the page proofs are returned to the production office. Offprint orders will be processed once the manuscript is published and payment received. Contributors must submit their manuscripts online. Authors must create an account (or, for previous Molecular Medicine authors or reviewers, check for an existing account) at the Molecular Medicine online submission site: http://mc.manuscriptcentral.com/molmed. The submission system asks for information about the manuscript as noted below, after which contributors will need to upload files related to their submission. While online submission can accommodate a variety of file types, authors are urged to provide their manuscripts as original Microsoft Word documents, and any tables, figures, and figure legends supplied, as original files (figures may also be submitted as Microsoft Powerpoint slides). Related manuscripts, figures, or other files should be uploaded separately. View Figure guidelines. A cover letter should identify the person (with address and telephone/fax number/e-mail) responsible for admin-istrative/scientific issues concerning the manuscript. The letter should make it clear that the submitted manuscript has been seen and approved by all authors; that authors have taken due care to ensure the integrity of the work; that the work is not under consideration elsewhere; that the national and institutional policies of humane care and use of laboratory animals have been abided by conscientiously; and, where applicable, include a statement that all human studies were approved by the appropriate institutional committee or that it complied with the Helsinki Declaration as revised in 1983. ARRIVE (Animal Research: Reporting of In Vivo Experiments) Guidelines are intended to improve the reporting of animal experiments. These guidelines have been developed by the NC3Rs (National Centre for the Replacement, Refinement and Reduction of Animals in Research) to improve standards of reporting and ensure that the data from animal experiments can be fully evaluated and utilized. The guidelines are primarily aimed at scientists writing up their research for publication or involved in peer review. The European Association of Science Editors (EASE) has developed multilingual Guidelines for Authors and Translators. The Guidelines are now available in multiple languages through a link on the ISAJE website (under Latest News). The guidelines are aimed to make scientific communication more efficient worldwide and to prevent scientific misconduct. MANUSCRIPT FEES Authors will alsp be assessed $600 U.S. for the first color page ($200 U.S. for each additional color page) following publication. (At their discretion, at proof stage, authors may choose to present color figures as grayscale images.) RNA FORMAT OF ORIGINAL ARTICLES Title and Authors' Names. The title page should include: title of the paper (15 words or less); a shortened version of the title for use as a running head (maximum 45 letter spaces); the name(s) of the author(s), including the first name(s); the name of the department(s) and institution(s) in which the work was done; the institutional affiliation of each author; and the name, address, telephone, fax number, and e-mail address of the author responsible for correspondence. Any change in author list (additions/deletions) after paper acceptance must be justified in writing to the editors. Five MeSH-Medline key words not included in the title should be listed. Abstract. The Abstract (250 words) should include the rationale, objectives, results, and conclusions of the study. The Abstract should read as a single, continuous piece and must not be broken into separate sections. Materials and Methods/Subheading. This section should include sufficient detail to allow another researcher to repeat the experiment. Biological studies: unambiguous identification of genus, species, and strain; the source of any organisms (cell line, animal stock); and age, sex, weight, and condition of organisms as appropriate. Research on animals should include a statement that the protocol was approved by the appropriate committee or complied with the Guide for the Care and Use of Laboratory Animals. Describe how animals were killed. Describe control and experimental subjects giving age, weight, sex, race, and for animals, breed or strain. Include the supplier of experimental animals. Clinical studies: pertinent details about human subjects, including methods of recruitment and relevant physical characteristics. Reports of human studies must include a statement that the protocol was approved by the appropriate institutional committee or that it complied with the Helsinki Declaration as revised in 1983. When preparing reports of randomized, clinical trials, authors should refer to the checklist published in the CONSORT Statement and should include a trial profile summarizing participant flow. General: unambiguous identification of nonbiological materials used (chemicals) including the source of such materials, the types of apparatus used, including model number and manufacturer for specialized equipment, the experimental procedure (by reference to a previous report using the same procedure or by detailed description), including potential hazards, if applicable; and the types of test performed, including statistical tests. Statistics. Papers with statistical testing should state the name of the test, the n for each analysis, the comparisons of interest, a justification for the use of that test, the alpha level for all tests, whether the tests were one- or two-tailed, and the actual P value for each test. Data sets should be summarized with descriptive statistics, which should include the n for each data set, a clearly-labeled measure of center (such as the mean or the median), and a clearly-labeled measure of variability (such as the standard deviation or range). Graphs should include clearly labeled error bars. Authors must state whether a number that follows the ± sign is a standard error of the mean (s.e.m.) or a standard deviation (s.d.). Acknowledgments. Sources of financial support should be included along with any acknowledgments relevant to scientific advice or assistance. Disclosure. Authors should include any necessary conflicts of interest. Footnotes. Footnotes should be restricted to the title page (affiliations, corresponding author) and within tables. Footnotes in the title page are assigned consecutive superscript numbers (i.e., 1, 2, 3, etc.). Footnotes in tables are assigned consecutive, superscript capital letters (i.e., A, B, C, etc.). References. References should be numbered consecutively as they are cited in the text and listed in parentheses. References first cited in tables or figure legends must be numbered so that they will be in sequence with references in the text. References should include full titles of the papers with inclusive page numbers. All authors should be listed when there are five or fewer; when there are six or more, the first author should be listed followed by "et al.'' Abbreviate the names of journals according to PubMed. Spell out names of unlisted journals. Do not number references to personal communications, unpublished data, and manuscripts either in preparation or submitted for publication. If essential, such material may be incorporated in the appropriate place in the text. References to personal communications must be accompanied by a letter from the communicator authorizing publication of comment. Manuscripts listed as in press should be numbered, but a copy of the text should be submitted along with the manuscript under consideration. Personal communications or unpublished observations can be cited in the text, but must be accompanied with a written permission.
Figures. Figures should be cited sequentially in the text using Arabic numerals. Figure legends should be listed one after the other, as part of the text document, separate from the figure files. Figure legends should include a short title and a brief explanation with sufficient detail to interpret the data presented. Do not exceed 350 words for each legend and provide a key for any symbols. Authors will be prompted by the system to submit all images or figures as separate documents. The required font for any text in the figure or image is Arial, non-serif. All image or figure panel labels (A, B, C, etc.) must be Arial, Bold and in the upper left hand corner of the figure. All electronic images should be high resolution (300-600 dpi). Please view the following documents for additional information on figure preparation: Tables. All Tables should be double-spaced each on its own page, portrait orientation, upright, with brief titles. Superscript capital letters should be used in consecutive order as footnotes as described above. Policies. Publication in Molecular Medicine implies that readily replaceable material described in the paper will be freely distributed to qualified academic researchers. Nucleic acid, RNA, and protein sequences should be deposited in appropriate databanks in time for the accession numbers to be included in the paper. Please see NCBI databases website for information at http://www.ncbi.nlm.nih.gov/Database/index.html. MISSION COPTRIGHT NOTICE/PERMISSIONS (return to top) Molecular Medicine requires that authors transfer copyright to the journal as a condition of publication in accordance with 17 U.S.C. §204(a). As difficult as it can be to collect the signature of every author, it is unlikely that the task will ever be easier. Thus, by controlling the copyright of articles published in Molecular Medicine, we make it easier for others to secure permission to reprint Molecular Medicine articles. In addition, as a publisher, we must know that all authors are involved in its publication. Molecular Medicine articles may be freely copied, in whole or in part, for the purposes of education or research provided that (1) the copies include complete bibliographical information for the article; (2), the copied material is not republished; and (3), the copies are not sold. To secure permission to reprint an article published in Molecular Medicine, please contact our editorial office. Copyright infringement is a violation of federal law and is subject to criminal and civil penalties. FORMS (return to top)
Molecular Medicine is owned and published by The Feinstein Institute for Medical Research. Upon acceptance for publication in Molecular Medicine, the copyright on the published work is assigned to The Feinstein. PRE-SUBMISSION ENQUIRY SERVICE The pre-submission enquiry service is a courtesy and is not required prior to full submission. Pre-submission enquiries can be difficult to assess reliably and Molecular Medicine Editors cannot make an absolute commitment to have a contribution refereed before seeing the entire paper. Entire papers should not be sent as pre-submission enquiries, but be submitted through our online submission system: http://mc.manuscriptcentral.com/molmed Molecular Medicine, cannot guarantee the response time for pre-submission enquiries, but usually tries to provide a response within five working days. There is no appeal process for resubmission enquiries, however, authors who have received a negative response may formally submit the manuscript if they wish. CONTACT US (return to top)
|
|
| Processing Fee ($500) |
||
| First Color Charge ($600) |
||
| Additional Color Charge ($200 each) | ||
|
